Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Elan PharmaInternational, a subsidiary of Elan Corporation, has resolved its patent dispute over Abraxane with Celgene, under a settlement and licensing agreement signed between both the parties.
Subscribe to our email newsletter
Elan filed the patent litigation case against Abraxis BioScience in 2006, which was acquired by Celgene in October 2010.
In consideration of the terms of the settlement and license agreement, Celgene will pay Elan a one-time fee of $78m.
Further, Elan will not receive any additional payments for sales of Abraxane, or any other nab-Paclitaxel product in the US or globally.
Celgene will take over a fully-paid up, exclusive, world-wide license to select Elan US and foreign patents for Abraxane.